Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies
March 04 2021 - 09:14AM
InvestorsHub NewsWire
San Francisco, CA -- March 4, 2021 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC:
ONPH) is pleased to announce initiation of formal drug
development and preclinical planning for its lead drug product,
based upon proprietary nanoemulsion technology licensed from
NanoSmart Pharmaceuticals. Oncology Pharma will be providing
the initial funds to develop and evaluate a dactinomycin
nanoemulsion drug product. A version of this product
originally received FDA Orphan Drug Designation in 2015.
Oncology Pharma has secured access to a broad range of
proprietary intellectual property with the potential to make novel
drug products to treat cancer that are both safer and more
effective than the original drug(s) currently in the market.
Oncology Pharma has initiated discussions with NanoSmart on
near-term goals including analytical method validation and drug
product characterization. Once complete, formal preclinical
safety and veterinary clinical studies will be pursued. Veterinary
drug development will serve a current and growing need for better
treatment options. Data from this project may also be applied
towards future regulatory approval to initial human clinical
studies for the same drug formulation.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California
corporation that is developing nanoparticle drug delivery platforms
that utilize anti-nuclear antibody (ANA) to target existing drug
therapies to areas of necrosis present in virtually all solid
cancer tumors.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Mar 2023 to Mar 2024